Whalesbook
Strong Domestic Sales Bolster Pharma Sector
India's pharmaceutical market showed robust growth in the final quarter of fiscal year 2026, with sales increasing 10.5% by March. This was the strongest quarterly performance in five periods, accompanied by improving volume growth of 1.7%. Domestic strength, especially in chronic therapy areas like cardiac and anti-diabetic treatments, is expected to grow by an estimated 12% year-on-year for key companies. This strong local demand is a crucial offset to the predicted slowdown in US revenues, according to analysts at Kotak Institutional Equities and Nuvama Institutional Equities. This domestic momentum is vital for companies such as Dr. Reddy's Laboratories, Sun Pharmaceutical Industries, and Cipla Ltd, who are expected to lead this growth.
US Market Faces Revenue Decline
Major Indian drugmakers expect their US revenue to shrink in the March 2026 quarter. The main reason is the expiry of the exclusive sales period for the important cancer drug, generic Revlimid. Although Indian firms like Dr. Reddy's, Cipla, and Sun Pharma had settlements allowing some Revlimid sales from 2022, the full patent expiry in January 2026 means remaining sales will directly impact figures. Analysts at India Ratings and Research predict this will slow US growth to 3-5% in FY2026, down from nearly 10% in FY2025. Companies must therefore speed up efforts to boost US growth by launching new drugs and developing pipelines to compensate for Revlimid's lost contribution, which previously generated substantial revenue and profits.
Geopolitics Disrupt Supply Chains, Raise Costs
Adding to US market challenges, escalating geopolitical tensions, especially the conflict in Iran, are straining global pharmaceutical supply chains. Disruptions to shipping and petrochemical supplies have sharply increased costs for Active Pharmaceutical Ingredients (APIs) and raw materials, with some ingredient prices jumping 26% to 100% since December 2025. Methanol supply is a particular concern. While companies usually hold substantial inventories, prolonged supply chain issues could further inflate logistics costs and potentially affect production. The pharma sector's reliance on petrochemicals means that even indirect impacts, like crude oil refining disruptions, can ripple through the value chain. These complex supply chains may take several months to recover.
Sector Valuations and Returns
The Nifty Pharma index has outperformed the broader Nifty 50 over the past year, showing the sector's underlying strength and growth drivers. The Nifty Pharma index returned about 48% in the last twelve months, versus 26% for the Nifty 50. However, current sector valuations present a mixed view. The Nifty Pharma index trades at a P/E ratio of 33.28, while the BSE Healthcare index has a projected P/E of around 24x. Among major companies, Dr. Reddy's Laboratories trades at a P/E of roughly 17.09x, Cipla at about 21.66x, and Torrent Pharmaceuticals at a much higher 60.00x P/E. This difference in valuation may indicate premium pricing for expected growth or varying risk assessments. Although domestic demand is strong, overall EBITDA margins for the sector are forecast to drop by 1.78 percentage points to 23.1% in Q4 FY26, due to US price drops and operational challenges.
Profitability Risks and Valuation Concerns
While domestic growth remains positive, profitability faces significant risks. The loss of Revlimid patent exclusivity in the US not only reduces revenue but also impacts high-margin earnings, vital for reinvestment. Companies heavily dependent on this drug may struggle with margin pressure as they seek alternative revenue streams. Additionally, geopolitical instability and supply chain disruptions are causing unpredictable cost increases, with companies already reporting higher input and packaging expenses. A major concern is whether domestic growth can fully offset these US revenue dips and rising operational costs. Failing to manage these combined pressures could lead to slower earnings growth, making current valuations seem high, particularly for companies like Torrent Pharmaceuticals with its elevated P/E ratio. Successful navigation of market shifts and effective cost management will be crucial for companies like Dr. Reddy's, Sun Pharma, Cipla, Torrent Pharma, and Lupin.
Outlook: Domestic Strength Meets Global Challenges
The outlook for India's pharmaceutical sector is cautiously optimistic, hinging on the balance between sustained domestic market growth and the ability to manage US market pressures and supply chain volatility. Analysts predict revenue growth for Indian drugmakers between 7-10% for FY2026, with domestic sales driving this expansion. However, profit margins face pressure, with a predicted 6% drop in net profit and only 3% EBITDA growth for Q4 FY26 by Nuvama Institutional Equities. The sector's future success will depend on its agility in adapting to global changes, managing fluctuating raw material costs, leveraging its domestic position, and strategically addressing US market challenges.